An Unusual Complication of Cabergoline Treatment of Macroprolactinomas

Amal Moumen, Sanae Chakdoufi, Hamza El Jadi, Ouijdane Zammani, Cherif Abad El Asri, Ghizlaine Belmejdoub

Abstract


Dopamine agonist (DA) treatment is the first choice treatment of prolactinomas. Optic chiasm prolapse with secondary visual deterioration is an unusual and rare complication of DA treatment. A 40-year-old man with giant prolactinoma was successfully treated by cabergoline. After 14 months, he presented with a visual impairment with no ophthalmologic anomalies that could explain this worsening. The pituitary magnetic resonance imaging (MRI) revealed an important shrinkage of prolactinoma with a prolapse and a central atrophy of optic chiasm secondary to the adenoma shrinkage. This case highlights the need of regular assessment of visual field all along cabergoline treatment of macroprolactinomas despite initial improvement or even normalization of visual field, to promptly identify an optic chiasm prolapse and avoid the optic chiasm atrophy.




J Endocrinol Metab. 2021;11(2):52-55
doi: https://doi.org/10.14740/jem730

Keywords


Cabergoline; Optic chiasm prolapse; Macroprolactinoma

Full Text: HTML PDF
 

Browse  Journals  

 

Journal of Clinical Medicine Research

Journal of Endocrinology and Metabolism

Journal of Clinical Gynecology and Obstetrics

 

World Journal of Oncology

Gastroenterology Research

Journal of Hematology

 

Journal of Medical Cases

Journal of Current Surgery

Clinical Infection and Immunity

 

Cardiology Research

World Journal of Nephrology and Urology

Cellular and Molecular Medicine Research

 

Journal of Neurology Research

International Journal of Clinical Pediatrics

 

 
       
 

Journal of Endocrinology and Metabolism, bimonthly, ISSN 1923-2861 (print), 1923-287X (online), published by Elmer Press Inc.                     
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)


This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.jofem.org   editorial contact: editor@jofem.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.